Viewing Study NCT05633602


Ignite Creation Date: 2025-12-25 @ 3:47 AM
Ignite Modification Date: 2026-03-09 @ 2:44 PM
Study NCT ID: NCT05633602
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-28
First Post: 2022-11-21
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Sponsor: SWOG Cancer Research Network
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Recurrent Lung Non-Small Cell Carcinoma View
None Stage IV Lung Cancer AJCC v8 View
Keywords: